Login to Your Account

Jardiance CV death risk vote nears for FDA advisors

By Michael Fitzhugh
Staff Writer

Friday, June 24, 2016

FDA reviewers told agency advisors in briefing docs released Friday that Jardiance (empagliflozin) postmarket data show "substantial evidence" that, for certain adults with type 2 diabetes, the drug reduces the risk of cardiovascular death.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription